Scott Scarneo
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$8.6MFederal grants as PI11 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
11 awards · $8.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 16, 2026 | NIH | SBIR Phase I Development of a novel, orally bioavailable, TAK1 inhibitor for the treatment of chemotherapy-induced peripheral neuropathy | $406K | EydisBio, Inc. |
| Jul 16, 2025 | NIH | SBIR Phase II Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease | $1.4M | EydisBio, Inc. |
| Sep 12, 2024 | NIH | STTR Phase I Development of orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's Disease | $506K | EydisBio, Inc. |
| Jul 10, 2024 | NIH | SBIR Phase II Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease | $1.2M | EydisBio, Inc. |
| Aug 11, 2022 | NIH | SBIR Phase II Preclinical Development of the TAK1 Inhibitor HS-276 for the Treatment of Rheumatoid Arthritis | $913K | EydisBio, Inc. |
| Jul 15, 2022 | NIH | SBIR Phase I Acute Inhibition of TAK1 as a Means to Control COVID-19 Pulmonary Hyperinflammation | $285K | EydisBio, Inc. |
| Sep 22, 2021 | NIH | SBIR Phase II Preclinical Development of the TAK1 Inhibitor HS-276 for the Treatment of Rheumatoid Arthritis | $797K | EydisBio, Inc. |
| Sep 22, 2021 | NIH | SBIR Phase II Preclinical Development of the TAK1 Inhibitor HS-276 for the Treatment of Rheumatoid Arthritis | $1.7M | EydisBio, Inc. |
| Sep 8, 2021 | NIH | SBIR Phase I Evaluating the Blood-Brain Barrier Bioavailability and in vivo Efficacy Potential of a Novel TAK1 Inhibitor Targeting Chronic Pain | $481K | EydisBio, Inc. |
| Aug 1, 2021 | NIH | SBIR Phase I Acute Inhibition of TAK1 as a Means to Control COVID-19 Pulmonary Hyperinflammation | $594K | EydisBio, Inc. |
| Jul 29, 2021 | NIH | SBIR Phase I Acute Inhibition of TAK1 as a Means to Control COVID-19 Pulmonary Hyperinflammation | $309K | EydisBio, Inc. |
Peer ranks
Federal funding#96
Awards as PI#106
Patents#273
Companies
- EydisBio, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.